According to Precedence Research, the radiopharmaceuticals market size has been estimated at USD 7.51 billion in 2025 and is projected to reach approximately USD 14.44 billion by 2034, growing at a ...

The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

Curium announced today that the U.S. Food and Drug Administration approved its generic version of the Kit for the Preparation of Technetium ...

ST. LOUIS, April 02, 2025 (GLOBE NEWSWIRE) -- Curium announced today that the U.S. Food and Drug Administration approved its ...

PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...

The MHRA has approved the product for three clinical settings, including identifying how far high-risk prostate cancer has ...

ARTMS will continue to support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes such as zirconium-89 (89 Zr), gallium-68 (68 Ga), ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

UK MHRA approves trofolastat for diagnostic imaging of prostate cancer in men: United Kingdom Monday, March 31, 2025, 15:00 Hrs [IST] The Medicines and Healthcare products Regulat ...

Frontier Science Center for Rare Isotopes, School of Nuclear Science and Technology, Lanzhou University, Lanzhou 730000, China Frontier Science Center for Rare Isotopes, School of Nuclear Science and ...

Trofolastat is combined with the radioactive tracer technetium-99m to form Technetium (99mTc) trofolastat, which is administered as a single injection. It binds to a protein called PSMA found on ...